Relugolix, Estradiol And Norethindrone Acetate

Introduction Overview

Generic Name

relugolix, estradiol and norethindrone acetate

Brand Name

Myfembree

Dosage Form

tablets

Drug Class

Sex hormone combinations

Pharmacokinetics

Absorption: Myfembree's pharmacokinetics primarily pertain to its three active components: relugolix, estradiol, and norethindrone acetate. Relugolix is rapidly absorbed after oral administration, reaching peak plasma concentrations typically within 1-2 hours. The bioavailability is influenced by first-pass metabolism and interactions with P-glycoprotein (P-gp) transporters, necessitating dosage timing considerations when co-administered with P-gp inhibitors. Estradiol, administered as a component in the tablet, is effectively absorbed in the gastrointestinal tract, mimicking endogenous estradiol pharmacokinetic profiles, though its oral bioavailability is affected by extensive first-pass hepatic metabolism. Norethindrone acetate, a prodrug of norethindrone, is similarly absorbed with peak levels achieved approximately 1-2 hours post-dose. Food intake does not significantly affect the absorption of Myfembree, allowing flexible administration with or without meals.

Distribution: Once absorbed, relugolix exhibits moderate plasma protein binding, primarily to albumin and alpha-1 acid glycoprotein, allowing for systemic distribution with particular affinity to the hypothalamic-pituitary-gonadal axis where it exerts its effects. Estradiol is highly protein-bound, chiefly to sex hormone-binding globulin (SHBG) and albumin, facilitating widespread tissue distribution including target reproductive tissues and bone. Norethindrone also binds extensively to serum albumin and SHBG, contributing to its pharmacologic activity and tissue penetration. The volume of distribution for each component allows for effective receptor interaction while minimizing peripheral tissue accumulation. Distribution is an important factor in modulating both therapeutic and adverse profiles.

Metabolism: Relugolix undergoes hepatic metabolism predominantly via CYP3A4 and other phase I enzymes, as well as by UGT1A enzymes mediating glucuronidation, facilitating its inactivation and excretion. Estradiol is metabolized hepatically with conversion to estrone, estriol, and conjugated metabolites via sulfation and glucuronidation pathways. The progestin norethindrone acetate is rapidly deacetylated to norethindrone, which is then metabolized by hepatic enzymes primarily involving reduction and conjugation reactions. Metabolic pathways of these steroids and the GnRH antagonist relugolix can be influenced by concomitant medications that alter cytochrome P450 activity, impacting systemic exposure and efficacy.

Elimination: The elimination of Myfembree components occurs mainly through renal and fecal routes following hepatic metabolism. Relugolix has a terminal half-life of approximately 37-42 hours allowing once-daily dosing; it is eliminated via biliary excretion into feces and renal clearance. Estradiol metabolites are excreted predominantly via urine as conjugates, while norethindrone and its metabolites are eliminated in urine and feces as well. The prolonged half-life and steady-state pharmacokinetics support consistent hormonal suppression, with careful monitoring required in patients with hepatic or renal impairment. Dose adjustments have not been clearly established but cautious use and clinical monitoring are advised.

Dosage Forms

Available Dosage Forms: Myfembree is available exclusively as oral tablets formulated with fixed doses of three active ingredients per tablet: relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg. The tablets are intended for once-daily oral administration.

Dosages for Adults and Adolescents: The standard prescribed dosage for adult premenopausal women is one tablet orally once daily. This dosing regimen is applicable both for the management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids) and for the treatment of moderate to severe pain due to endometriosis. There are no dosage modifications recommended for adolescents under 18 years as safety and efficacy have not been established in pediatric populations.

Specific Patient Populations: Use in special populations requires clinical discretion. Myfembree is contraindicated in patients with severe hepatic impairment due to metabolism pathways of steroid hormones and relugolix. There is limited data on use in renal impairment; thus, use cautiously. The drug is not recommended during pregnancy or breastfeeding due to potential fetal risks and drug passage into breast milk. Elderly women typically beyond premenopausal age are not indicated for treatment with Myfembree. No dose adjustments have been formally recommended based on body weight or race, but careful monitoring for adverse effects is prudent.

Additional Administration Notes: Patients should initiate therapy within 7 days of menstrual onset to optimize treatment effect, with attention to possible irregular bleeding during the first month of use. Administration time should remain consistent daily to maintain steady-state drug levels. If taking P-glycoprotein inhibitors, dosing should be separated by at least 6 hours to avoid interaction affecting absorption.

Mechanism Of Action

Myfembree is a combination oral medication comprising relugolix, estradiol, and norethindrone acetate designed to synergistically manage symptoms related to uterine fibroids and endometriosis in premenopausal women.

Relugolix is a potent, orally active, non-peptide gonadotropin-releasing hormone (GnRH) receptor antagonist. It exerts its therapeutic effect by competitively blocking GnRH receptors in the anterior pituitary gland. This blockade results in rapid suppression of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion, leading to decreased ovarian production of estradiol and progesterone. The reduction in circulating estradiol attenuates estrogen-dependent growth of uterine fibroids and endometriosis lesions, thus reducing bleeding and pain symptoms.

Estradiol in Myfembree is administered exogenously at a low dose to mitigate the hypoestrogenic effects caused by relugolix-induced ovarian suppression, particularly to reduce risks of bone mineral density loss and vasomotor symptoms like hot flushes. Estradiol binds to estrogen receptors (ERα and ERβ) in target tissues, supporting normal physiological functions, including maintenance of bone density and vascular health.

Norethindrone acetate, a synthetic progestin, is included to counterbalance the proliferative effects of estradiol on the endometrium, reducing the risk of endometrial hyperplasia and abnormal bleeding. It binds to progesterone receptors, inducing decidualization and maintenance of endometrial stability. This hormonal combination thus preserves the beneficial effects while minimizing adverse endometrial proliferation.

Collectively, Myfembree’s mechanism leverages hormonal modulation by suppressing endogenous GnRH signaling, supplementing estrogen replacement to prevent bone loss, and adding progestin to safeguard endometrial integrity. This comprehensive approach results in substantial reduction in heavy menstrual bleeding and pain associated with uterine fibroids and endometriosis. Clinical studies have demonstrated significant symptomatic improvement compared to placebo, highlighting the efficacy of this combination therapy. Compared to GnRH agonists, relugolix provides a rapid onset of symptom relief without an initial testosterone flare and with oral convenience, representing a substantial therapeutic advancement.

Pharmacological Actions

Oral GnRH receptor antagonism leading to rapid suppression of LH and FSH secretion.
Reduction of ovarian estradiol and progesterone synthesis, lowering systemic estrogen levels.
Exogenous estradiol supplementation to maintain bone mineral density and reduce menopausal symptoms.
Progestin-induced endometrial protection preventing hyperplasia during estrogen therapy.
Modulation of sex hormone levels to reduce uterine fibroid-related heavy bleeding.
Attenuation of endometriosis-associated inflammation and lesion pain via hormonal suppression.
Improvement in menstrual cycle regulation in premenopausal women with fibroids or endometriosis.
Minimization of estrogen deficiency adverse effects through balanced hormone replacement.
Exertion of anti-fibrotic effects mediated by hormonal environment alteration.
Effect on hypothalamic-pituitary-gonadal axis with reversible hormone suppression.
No significant androgenic, glucocorticoid, or mineralocorticoid receptor activity noted.
Dose-dependent modulation of hormone levels with once-daily oral administration.

Therapeutic Or Clinical Uses

Management of heavy menstrual bleeding due to uterine leiomyomas (fibroids) in premenopausal women.
Treatment of moderate to severe pain associated with endometriosis in premenopausal women.
Reduction of uterine bleeding volume and duration in patients with symptomatic fibroids.
Alleviation of dysmenorrhea and pelvic pain related to endometriosis lesions.
Hormonal therapy option for women desiring medical management of hormone-dependent gynecologic conditions.
Alternative to surgical interventions such as hysterectomy or myomectomy for fibroids.
Management of endometriosis-related symptoms in women seeking non-invasive treatment.
Improvement in quality of life by reducing menstrual blood loss and associated anemia.
Control of fibroid symptomatology without inducing estrogen deprivation side effects.
Short-term therapy not exceeding 24 months to balance clinical benefits against bone density risk.
Option for women contraindicated for estrogen-only therapies due to progestin inclusion.
Adjunctive therapy where traditional progestins or GnRH analogs are insufficient or poorly tolerated.
Symptom management in women with intact uterus requiring combined hormonal therapy.

Side Or Adverse Effects

Hot flushes and increased sweating including night sweats due to hypoestrogenic state.
Abnormal vaginal bleeding characterized by prolonged, heavy, or irregular bleeding.
Hair loss (alopecia) and hair thinning occurring during treatment, with uncertain reversibility.
Decreased libido or reduced interest in sexual activity observed in some patients.
Mood changes including depression, worsening anxiety, and rare reports of suicidal ideation.
Headache episodes and migraine exacerbation reported in a subset of users.
Nausea and gastrointestinal discomfort with occasional vomiting.
Back pain and joint pain (arthralgia) reported as musculoskeletal side effects.
Dizziness and fatigue contributing to overall decreased patient wellbeing during therapy.
Elevated blood pressure necessitating regular monitoring during treatment course.
Abnormal liver function tests including signs of hepatotoxicity: jaundice, fatigue, dark urine.
Gallbladder disorders such as cholestasis, particularly in patients with prior history.
Risk of blood clot formation (venous thromboembolism) with signs such as leg swelling or chest pain.
Potential increase in blood sugar, cholesterol, and triglyceride levels requiring metabolic assessment.
Uterine fibroid expulsion or prolapse leading to severe bleeding and cramping events.

Precautions

Monitor bone mineral density regularly due to risk of decreased estrogen-mediated bone loss.
Avoid use longer than 24 months to minimize irreversible bone density reduction.
Do not take during pregnancy or if attempting conception due to risk of fetal harm and pregnancy loss.
Routine pregnancy testing recommended prior to and during treatment.
Use reliable non-hormonal contraception during therapy and for one week post-treatment cessation.
Avoid concurrent use of hormonal contraceptives to prevent additive side effects and reduced efficacy.
Screen and monitor for cardiovascular risk factors, especially in women over 35 who smoke.
Discontinue treatment prior to surgery or prolonged immobilization to reduce thrombosis risk.
Periodic evaluation of liver function tests for early detection of hepatic adverse effects.
Assess mental health status due to potential for mood alterations including suicidal ideation.
Regularly monitor blood pressure and metabolic parameters such as lipid and glucose levels.
Exercise caution in women with history of migraines, especially migraine with aura.
Evaluate vaginal bleeding etiology before initiating therapy to exclude malignancy or undiagnosed causes.
Medication reconciliation to identify potential interacting drugs that could alter Myfembree exposure.
Advise patients on signs of thromboembolism and instruct immediate medical consultation if symptoms appear.

Warnings

Increased risk of serious cardiovascular events: myocardial infarction, stroke, venous thromboembolism.
Potential for significant bone mineral density loss with prolonged therapy.
Not safe for use in pregnancy; risk of early pregnancy loss and fetal harm.
Risk of severe allergic reactions including angioedema and anaphylaxis to components.
Possibility of severe mood and behavioral changes including suicidal thoughts and depression.
Serious hepatic adverse effects including cholestasis, hepatic dysfunction, and elevated liver enzymes.
Uterine fibroid prolapse or expulsion leading to acute vaginal bleeding and pelvic pain.
Warning against use in patients with poorly controlled hypertension or diabetes with vascular complications.
Contraindicated in women with known or suspected hormone-sensitive cancers.
Risk of worsening migraine headaches with aura, especially in women over 35 years.
Smoking combined with age over 35 significantly raises incidence of thrombotic complications.
Potential alteration of thyroid and steroid hormone levels may necessitate dose adjustments of concomitant therapies.
Do not co-administer with P-gp inhibitors without appropriate timing to avoid altered drug pharmacokinetics.
Discontinue immediately if any signs of blood clots, vision changes, or neurological symptoms develop.
Ensure thorough patient education on symptom recognition indicative of life-threatening side effects.

Contraindication

History or presence of blood clots including deep vein thrombosis, pulmonary embolism, or retinal thrombosis.
Prior stroke or myocardial infarction indicating established cardiovascular disease.
Conditions causing hypercoagulability or blood clotting disorders.
Blood circulation disorders associated with increased thrombotic risk.
Severe cardiac valve disease or heart rhythm abnormalities predisposing to clot formation.
Severe uncontrolled hypertension despite pharmacologic treatment.
Diabetes mellitus with end-organ damage including kidney, eye, nerve, or vascular complications.
Migraine with aura, especially in women older than 35, or severe migraine headaches.
Known or suspected breast cancer or any estrogen/progestin-sensitive malignancy.
Existing osteoporosis compromising bone strength and increasing fracture risk.
Unexplained abnormal vaginal bleeding pending diagnosis.
Active liver disease or impaired hepatic function.
Smoking in women older than 35 years of age due to elevated stroke and clotting risk.
Known hypersensitivity or allergic reaction to relugolix, estradiol, norethindrone acetate, or any tablet excipients.
Pregnancy or lactation where drug exposure is contraindicated.

Drug Interactions

Oral P-glycoprotein (P-gp) inhibitors such as azithromycin, clarithromycin, erythromycin, itraconazole, and ketoconazole may increase relugolix plasma levels, requiring administration of Myfembree at least 6 hours before these drugs.
Antiviral agents used for HIV or hepatitis C treatment can alter metabolism and plasma levels of active components.
Certain oral chemotherapeutic agents may have altered efficacy or increased toxicity when combined with Myfembree.
Cardiac drugs such as amiodarone, carvedilol, captopril, dronedarone, propafenone, quinidine, ranolazine, ticagrelor, and verapamil may interact through cytochrome P450 pathways affecting drug concentrations.
Medications for cystic fibrosis potentially influence metabolism through hepatic enzyme induction or inhibition.
Immunosuppressants used to prevent organ transplant rejection can interact by modifying cytochrome P450 activity.
Use of additional hormonal contraceptives is contraindicated due to increased risk of side effects and reduced efficacy.
Vitamin and herbal supplements may interfere with hormone metabolism or liver enzyme function.
CYP3A4 inducers such as rifampin and certain anticonvulsants may reduce estradiol and norethindrone levels, decreasing therapeutic effect.
Drugs affecting coagulation pathways may exacerbate thrombotic risks when combined with Myfembree.
Concomitant use of corticosteroids may require dose adjustments due to altered steroid metabolism.
Interactions with thyroid hormone replacement may necessitate monitoring and dose modification.
Hepatotoxic drugs used concurrently increase risk of liver injury and require close monitoring.
Drugs that alter gut motility or pH may affect oral absorption of Myfembree components.
Co-administration with agents that prolong QT interval may increase cardiac arrhythmia risk.

Preparations Of The Drug

Myfembree tablets containing fixed-dose combination: relugolix 40 mg, estradiol 1 mg, norethindrone acetate 0.5 mg per tablet.
Formulated for oral administration with inert excipients including lactose monohydrate, mannitol, sodium starch glycolate, hydroxypropyl cellulose, magnesium stearate, hypromellose, titanium dioxide, triacetin, and iron oxide yellow.
Packaged in blister packs or bottles to maintain tablet stability between 59°F to 86°F (15°C to 30°C).
Supplied exclusively as prescription medication requiring healthcare provider oversight for dispensing.
Not formulated for pediatric dosing; intended for premenopausal adult women.
No intravenous, injectable, or alternative dosage forms currently available.
Manufactured with quality controls adhering to FDA-approved standards for purity, potency, and uniformity.
Includes comprehensive patient information leaflet outlining dosing instructions, side effects, and precautions.
Storage instructions emphasize protection from moisture and excessive heat to preserve tablet integrity.
Disposal guidelines recommend community pharmaceutical take-back programs or FDA recommendations for unused medication.
No generic formulations currently available; proprietary formulation under patent protection.
Available in unit-dose packaging to facilitate adherence to once-daily dosing regimen.
Packaging designed with child-resistant features to prevent accidental ingestion.
Contains non-hormonal excipients compatible with oral ingestion and minimal allergenicity risks.
Prepared for daily administration with or without food due to stable pharmacokinetic profile.